Pharmacokinetics of mangiferin and its metabolite—Norathyriol, Part 1: Systemic evaluation of hepatic first‐pass effect in vitro and in vivo

The Discussion (p. unavailable) concludes that hepatic first-pass metabolism plays a negligible role in MGF’s poor bioavailability, contrary to the claim of extensive first-pass metabolism. Results §3.3.2 (p. unavailable) reports that intestinal bacteria produced norathyriol slowly—only 0.1% of the added MGF after 72 hours—while parent MGF changed very little. The paper therefore does not support substantial depletion of parent MGF by either process. (LLM, conf=0.90)

Checked by a reasoning model — may be wrong.

The Introduction reports 33 mangiferin metabolites in samples from orally dosed rats and lists dehydroxylation, methylation, glucuronidation, and sulfation among their biotransformations. It does not specify O-methylation or state that these additional metabolites have distinct physicochemical properties. (LLM, conf=0.84)

The Discussion reports that hepatic first-pass metabolism contributes little to mangiferin’s poor bioavailability in rats, while intestinal bacteria generate norathyriol. It does not establish that the relative contribution of metabolic routes depends on species, dose, or formulation; its discussion of repeated dosing concerns possible metabolite accumulation, not a change in route contribution. Page numbers were not available in our copy. (LLM, conf=0.83)

The Introduction reports very low oral bioavailability, and the Abstract says norathyriol’s exposure and possible effects after repeated dosing require further study. The Discussion reports limited accumulation in the liver. These passages concern rat dosing and liver measurements; they do not establish uncertainty about exposure at clinically relevant doses, penetration into other target organs, or variability between formulations. Page numbers are unavailable in the indexed passages. (LLM, conf=0.86)

The Introduction (page unavailable) reports glucuronidation and sulfation among MGF’s metabolic pathways and notes its low bioavailability. But the Results (§3.3.2) find little MGF metabolism in rat hepatocytes, and the Discussion (§4) says hepatic first-pass metabolism likely plays an extremely limited role in its poor bioavailability. The paper therefore does not establish that metabolic lability and conjugation curtail exposure to parent MGF. (LLM, conf=0.83)

The citation is attached to the assertion that M1 formation is well documented; the qualification about a ‘predominant rather than obligatory’ event is the citing authors’ own framing. The Introduction and Discussion describe formation of norathyriol (NTR) from mangiferin, but our copy does not identify NTR as M1 or otherwise document formation of a metabolite called M1 (searched: M1, initial metabolite, metabolic scheme). (LLM, conf=0.76)